|
Advances in the Molecular Pharmacology and Therapeutics
of Bone Disease
6-7 July 2005
and
International Symposium on Paget’s Disease
8-9 July 2005
St Catherine’s College, Manor Road, Oxford,
UK
Full Programme
Conference Details
Wednesday Thursday Friday Saturday
Wednesday 6 July 2005
|
09.15
|
REGISTRATION AND COFFEE
|
|
09.50
|
Welcome
Graham Russell (Oxford, UK)
|
| |
Chairs: Richard Eastell (Sheffield, UK)/Sol Epstein
(New York, USA)
|
10.00
|
Cellular coupling revisited. Communication between osteoblasts
and osteoclasts
Jack Martin (Melbourne, Australia)
|
|
10.30
|
Estrogen receptor pharmacology
Donald McDonnell (Durham, USA)
|
|
11.00
|
SERMs Where next?
Henry Bryant (Indianapolis, USA)
|
|
11:30
|
Advances in Vitamin D pharmacology
Roger Bouillon (Leuven, Belgium)
|
|
12:00
|
The applications of phosphonate chemistry to bone pharmacology
Hal Ebetino (Cincinnati, USA)
|
|
12.45
|
LUNCH
|
| |
Chairs: Willy Hofstetter (Berne, Switzerland & Oxford,
UK)/Michael Horton (London, UK)
|
|
14.00
|
Neuro pharmacology and bone
Ian Reid (Auckland, New Zealand)
|
|
14.30
|
Prostaglandins and bone in 2005
Larry Raisz (Farmington, USA)
|
|
15.00
|
Genetic disorders of mineralisation
Matthew Brown (Oxford, UK)
|
15.30
|
TEA
|
| |
Chairs: Jack Martin (Melbourne, Australia)/Maureen
Owen (Oxford, UK)
|
|
16.00
|
Therapeutic strategies based on blockade of the RANKL/RANK/OPG
system
Lorie Fitzpatrick (Thousand Oaks, USA)
|
16.30
|
Approaches to anabolic agents for bone
Roland Baron (New Haven, USA)
|
17.00
|
Approaches to anabolic drugs via statins and the proteasome
pathways
Ross Garrett (San Antonio, USA)
|
17.30
|
CLOSE
|
20.00
|
Reception and Conference Dinner
(St Catherine’s College)
|
Thursday 7 July 2005
| |
Chairs: Matthew Brown (Oxford, UK)/Raj Thakker (Oxford,
UK)
|
|
09.00
|
Molecular mechanisms of PTH action
Jude Onyia (Indianapolis, USA)
|
09.30
|
Dual acting bone agents
René Rizzoli (Geneva, Switzerland)
|
|
10.00
|
The calcium sensing receptor as a drug target
Ed Nemeth (Toronto, Canada)
|
|
10.30
|
COFFEE |
| |
Chairs: Herbert Fleisch (Pully, Switzerland)/Graham
Russell (Oxford, UK)
|
|
11.00
|
Molecular insights into bisphosphonate actions
Michael Rogers (Aberdeen, UK)
|
|
11.30
|
Structural genomics and drug discovery
Udo Oppermann/Kate Kavanagh (Oxford,
UK)
|
|
12.00
|
Manipulating isoprenoid pathways
Said Sebti (Tampa, USA)
|
|
12.30
|
Novel approaches to inhibiting osteoclasts
Morten Karsdal (Copenhagen, Denmark)
|
13.00
|
LUNCH
|
| |
Chairs: Cyrus Cooper (Southampton, UK)/Harry Genant
(San Francisco, USA)
|
|
14.00
|
Update on osteoarthritis: pathogenesis and treatment
Tim Spector (London, UK)
|
|
14.30
|
Current and future therapies in arthritis and connective
tissue disease
Stephen Krane (Boston USA)
|
15.00
|
Approaches to muscle anabolics and their impact on the
skeleton
Gary Krishnan (Indianapolis, USA)
|
|
15.30
|
Engineering new tissues for bone and joint disease
Anthony Hollander (Bristol, UK)
|
|
16.00
|
CLOSE
|
|
|
|
Friday
8 July 2005
|
08:55
|
|
Welcome and introduction
Graham Russell (Oxford, UK)
|
09:00-10:30
|
Epidemiology and genetics
|
| |
|
Chairs: Henry Bone (Detroit, USA)/Peter Selby (Manchester,
UK)
|
09:00
|
IS1
|
UPDATE ON THE EPIDEMIOLOGY OF
PAGET’S DISEASE
Cyrus Cooper (Southampton, UK)
|
09:30
|
IS2
|
ASPECTS OF PATHOGENESIS OF PAGET’S
DISEASE
Tim Cundy (Auckland, New Zealand)
|
10:00
|
IS3
|
EPIDEMIOLOGY AND GENETICS OF PAGET’S
DISEASE IN ITALY
Luigi Gennari (Siena, Ialy)
|
10:20
|
P1
|
GENDER INFLUENCE IN SECULAR CHANGES
IN PAGET DISEASE
A Conesa, D Rotés Sala, J M Manresa, M P Lisbona, L Pérez Edo, J Carbonell
(Barcelona, Spain)
|
10:30
|
|
Coffee
|
11:00-12:55
|
Genetics
|
| |
|
Chairs: Jacques Brown (Quebec, Canada)/Matthew Brown
(Oxford, UK)
|
11:00
|
IS4
|
GENETICS AND ENVIRONMENTAL ORIGINS
OF PAGET’S DISEASE
Stuart Ralston (Edinburgh, UK)
|
11:30
|
IS5
|
SEQUESTOSOME MUTATIONS IN PAGET’S
DISEASE
Jean Morissette (Quebec, Canada)
|
11:55
|
P2
|
MUTATIONAL ANALYSIS OF P62/SEQUESTOSOME1
GENE P62/SQSTM1) IN A MULTICENTRIC ITALIAN SERIES OF PATIENTS
AFFECTED BY PAGET'S DISEASE OF BONE (PDB)
A Falchetti, F Marini F, F Del Monte, D Strigoli, A Gozzini, A Tanini,
L Masi, A Amedei, M Di Stefano, G Isaia, G B Rini, M L De Feo, S Maddali,
M Matucci Cerinic, M Benucci, A Matucci, G Marin, V Ferioli, M Ulivieri,
S Giannini, L Sartori, V Braga, S Adami, L Di Matteo, O Di Munno, S Ortolani,
M L Brandi (Florence, Turin, Palermo, Milan, Padua, Verona, Pescara and
Pisa, Italy)
|
12:05
|
P3
|
FUNCTIONAL EFFECTS OF PAGET'S
DISEASE SQSTM1 MUTATIONS
R Layfield, M S Searle, B Ciani, T Gallagher, P W Sheppard, L J Hocking,
S H Ralston, J R Cavey (Nottingham and Aberdeen, UK)
|
|
|
Short orals - Genetics
|
12:15
|
P4
|
SEGREGATION OF TWO DIFFERENT MUTATIONS
IN A SPANISH FAMILY WITH PAGET'S DISEASE
G Beyens, A Trujillo, W Van Hul (Antwerp, Belgium and Madrid, Spain)
|
12:23
|
P5
|
A NOVEL MUTATION (K378X) IN THE
SEQUESTOSOME 1 GENE ASSOCIATED WITH A SEVERE PHENOTYPE IN
PAGET'S DISEASE OF BONE
S L Morgan, L Ward, B K Ward, J Walsh, J Xu, B Stuckey, N Kent, T Ratajczak
(Nedlands, Australia)
|
12:31
|
P6
|
-511C>T POLYMORPHISM ON IL1B
GENE IS RELATED TO RESPONSE TO BISPHOSPHONATE TREATMENT IN
PAGET DISEASE OF BONE
L Corral Gudino, J del Pino, R Gonzalez Sarmiento, C A Montilla, I Pastor,
J García Aparicio (Salamanca, Spain)
|
12:39
|
P7
|
THE SEQUESTOSOME 1 MUTATION P392L
IS HETEROZYGOUS IN THE AFFECTED TISSUE
M Seton, M Smilewska, A Merchant, J Delany and M Hansen (Farmington,
USA)
|
12:47
|
P8
|
CHANGES IN GENE EXPRESSION IN
PAGETIC OSTEOBLASTS AND STROMAL CELLS
U Bava, D Naot, K E Callon, G D Gamble, D Wattie, I R Reid, R P Pitto,
S A McCowan, T Cundy, J Cornish (Auckland, New Zealand)
|
12:55-14:30
|
Lunch and posters
|
14:30-15:10
|
Experimental models
|
| |
|
Chairs: Richard Keen (London, UK)/Fred Singer (Los
Angeles, USA)
|
14:30
|
IS6
|
EXPERIMENTAL MODELS OF PAGET’S
DISEASE
David Roodman (Pittsburgh, USA)
|
15:00
|
P9
|
CANINE DISTEMPER VIRUS DOSE-DEPENDENTLY
INCREASES HUMAN OSTEOCLAST FORMATION AND FUNCTION IN VITRO
A P Mee (Manchester, UK)
|
15:10-16:00
|
Clinical features and diagnosis
|
| |
|
Chairs: Roger Francis (Newcastle upon Tyne, UK)/Roger
Smith (Oxford, UK)
|
15:10
|
IS7
|
MRI OF PAGET’S DISEASE OF
BONE
Sarah Burnett (London, UK)
|
15:40
|
P10
|
WHAT DOES THE BONE SCAN TELL US
WHEN MONITORING PAGET’S DISEASE
D Pearson D Hosking K Griffiths (Nottingham, UK)
|
15:50
|
P11
|
PAGET DISEASE OF BONE: CLINICAL
FEATURES IN A HIGH PREVALENCE FOCUS
J del Pino-Montes, L Corral, A Carpio, M J García-Rodríguez, L Pozo,
C A Montilla (Salamanca, Spain)
|
16:00
|
|
Tea
|
16:30-17:00
|
The PRISM Study
|
| |
|
Chairs: Michael Davie (Oswestry, UK)/Eugene McCloskey
(Sheffield, UK)
|
16:30
|
IS8
|
THE PRISM STUDY: BASELINE ANALYSIS
AND IDENTIFICATION OF CLINICAL PREDICTORS OF QUALITY OF LIFE
Anne Langston (Aberdeen, UK)
|
17:00
|
|
Keynote Lecture
|
| |
|
Chairs: Michael Davies (Manchester, UK)/Allan Dixon
(Truro, UK)
|
|
|
THE PAGET FAMILY ACROSS THE GENERATIONS
Sir Julian Paget
|
17:30
|
|
Close
|
19.30
|
|
Reception and Conference Dinner
|
|
Saturday
9 July 2005
|
09:00-10:30
|
Advances in biology and pharmacology
related to Paget’s disease
|
| |
|
Chairs: Claus Christiansen (Ballerup, Denmark)/Graham
Russell (Oxford, UK)
|
09:00
|
IS9
|
BONE STRUCTURE AND REMODELING
IN PAGET'S DISEASE - QUALITATIVE AND QUANTITATIVE ABNORMALITIES
IN OSTEOBLAST FUNCTION
Michael Parfitt (Little Rock, USA)
|
09:30
|
IS10
|
BISPHOSPHONATE PHARMACOLOGY
Jonathan Green (Basel, Switzerland)
|
10:00
|
IS11
|
BISPHOSPHONATE ACTIONS AND PAGET’S
DISEASE
Michael Rogers (Aberdeen, UK)
|
10:30
|
|
Coffee
|
11:00-12:30
|
Advances in treatment
|
| |
|
Chairs: Richard Eastell (Sheffield, UK)/Ian Reid (Auckland,
New Zealand)
|
11:00
|
P12
|
THE UTILITY OF MEASURING BONE
BIOMARKERS (PROCOLLAGEN TYPE 1 N-TERMINAL PROPEPTIDE
AND N-TERMINAL TELOPEPTIDE OF TYPE 1 COLLAGEN) TO ASSESS THE
LONG TERM EFFECTS OF BISPHOSPHONATE TREATMENT ON BONE TURNOVER
IN PAGET'S DISEASE
J A Riordan, B F Murray, M J Mc Kenna, T J Mc Kenna (Dublin, Ireland)
|
11:10
|
P13
|
TREATMENT COSTS OF PAGET'S DISEASE
AS A MEASURE OF MORBIDITY
B Briesacher, D Orwig, M Seton, M Omar, K Kahler (Massachusetts, Maryland,
Boston and East Hanover, USA)
|
11:20
|
P14
|
ASSESSMENT OF THE USE OF BISPHOSPHONATES
IN THE MANAGEMENT OF PAGET’S DISEASE OF BONE – THE
DEVELOPMENT OF CLINICAL STUDY METHODOLOGIES TO ASSESS EFFICACY
AND SAFETY
P Richardson, K Zelenakas (Tokyo, Japan and East Hanover, USA)
|
11:30
|
IS12
|
EFFECTS OF ZOLEDRONATE/RISEDRONATE
ON QUALITY OF LIFE IN PAGET'S DISEASE OF BONE
|
|
|
Ken Lyles (Durham, USA)
|
12:00
|
IS13
|
ZOLEDRONATE AND RISEDRONATE IN
THE TREATMENT OF PAGET'S DISEASE
David Hosking (Nottingham, UK)
|
12:30
|
|
Close and lunch
|
ADDITIONAL POSTERS
|
|
P15
|
MORBIDITY IN PATIENTS WITH PAGET'S
DISEASE PRESENTING WITH AND WITHOUT SYMPTOMS
M Seton, D Dorer, C Cooper (Massachusetts, USA and Southampton, UK)
|
|
P16
|
CARDIOVASCULAR COMPLICATIONS OF
PAGET'S DISEASE OF BONE
D Merlotti, L Gennari, R Valenti, A Palazzuoli, B Galli, C Pondrelli,
E Ceccarelli, A Calabrò, V De Paola, G Martini, R Nuti (Siena, Italy)
|
|
P17
|
CLINICAL CRITERIA FOR THE DIAGNOSIS
OF PAGETIC BONE PAIN: SURVEY OF COLLABORATING CENTRES IN THE
PRISM STUDY
A L Langston, M K Campbell, W D Fraser, P L Selby, S H Ralston, and The
PRISM Trial Group (Aberdeen, Liverpool, Manchester and Edinburgh, UK)
|
|
P18
|
SECULAR CHANGES IN PAGET S DISEASE
OF BONE IN OUR AREA
A Conesa, D Rotés Sala, J M Manresa, M P Lisbona, L Pérez Edo, J Carbonell
(Barcelona, Spain)
|
|
P19
|
PREVALENCE OF PAGET'S DISEASE
OF BONE IN ITALY
M Di Stefano, L Gennari, D Merlotti, G Martini, C Tamone, S Bergui, R
Zatteri, R De Lucchi, C Baldi,A Vattimo, L Burroni, V De Paola, S Calabrò,
A Avanzati, R Nuti, G C Isaia (Turin and Siena, Italy)
|
|
P20
|
PAGET'S DISEASE IN AN ASIAN IN
THE UK
S J Iqbal, S Mulhbayer G McHugh, R Oldham and D Finlay (Leicester, UK)
|
Wednesday Thursday Friday Saturday
|
